It’s been a very busy, big and ambitious year for Bioasis Technologies Inc. (TSX-V.BTI, OTC:BIOAF, Forum) – a biopharmaceutical company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. And while much has been accomplished by this cutting-edge biotech in 2020, much more exciting news is expected in the pipeline for 2021.
In a relatively short period of time, the Company has generated real shareholder value by developing and commercializing its proprietary brain delivery technology – XB3 – to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.
In this must-hear end-of-year vodcast, Stockhouse Media’s Dave Jackson was joined by CEO Dr. Deborah Rathjen to talk more about the genesis of the amazing xB3 platform, its long-term investment potential, and all things Bioasis moving forward into 2021.
Podcast #32: Orefinders Resources
Podcast #31: Pacific North West Capital
Podcast #30: BioMark Diagnostics
Podcast #29: Brazil Resources
Podcast #28: Lattice Biologics
Podcast #27: Trevali Mining
Podcast #26: PyroGenesis Canada
Podcast #25: GTA Resources
Podcast #24: Manitok Energy
Podcast #23: Manitok Energy
Stockpod #22: PUDO
Stockpod #21: Canadian Platinum
Stockpod #20: EEStor Corporation
Stockpod #19: Alexandria Minerals
Stockpod #18: RepliCel Life Sciences
Stockpod #17: Trevali Mining
Stockpod #16: CardioComm Solutions
Stockpod #15: Golden Leaf
Stockpod #14: Canadian Innovation Exchange
Stockhouse Drunken Roundtable podcast, 13/08/15
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
U.S Property Podcast
Aligned Money Show
Dubai Property Podcast
The Ramsey Show
The Clark Howard Podcast